skip to Main Content

Neoadjuvant Chemo Leads to Encouraging Resection Rates in Pancreatic Adenocarcinoma

Newsfeed image, light gray text on dark gray background
Aggressively treating pancreatic cancer in the neoadjuvant setting with chemotherapy could improve disease control and increase resection rates, explained Davendra Sohal, MD, MPH, citing results of a recent National Clinical Trials Network phase II trial.

The phase II SWOG S1505 study examined early control of systemic pancreatic disease with neoadjuvant treatment with either modified (mFOLFIRINOX) or gemcitabine/nab-paclitaxel (Abraxane) in patients with resectable pancreatic ductal adenocarcinoma. Of the 147 patients who were initially enrolled, 29% were ineligible due to venous involvement, arterial involvement, and distant disease. Results showed that following neoadjuvant chemotherapy, 77% of patients went to surgery and 73% of them underwent resection. Read more . . . 

Back To Top